法国全国人群队列研究:新诊断胶质母细胞瘤的诊疗模式、预后因素及放疗-替莫唑胺治疗与生存的关联
该研究基于法国2008年新诊断并经组织学确诊的胶质母细胞瘤患者2053例,随访至2015年,描述诊疗模式与生存。中位总生存为11.2个月(95%CI 10.7-11.9);60%患者启动放疗-替莫唑胺同期治疗,其中44%启动替莫唑胺辅助治疗。非进展患者中,辅助替莫唑胺用满6周期即停者死亡风险显著高于继续治疗者(HR=1.5,95%CI 1.2-1.9)。
要点
- 2053例新诊断胶质母细胞瘤患者中,60%启动放疗-替莫唑胺同期治疗,其中44%启动替莫唑胺辅助治疗。
- 仅22%患者接受6周期或以上辅助替莫唑胺,其对应中位生存为25.5个月(95%CI 24.0-28.3)。
- 非进展患者中,辅助替莫唑胺用满6周期即停者死亡风险高于继续治疗者,HR=1.5(95%CI 1.2-1.9)。
核心结论
- 在非进展患者中,将辅助替莫唑胺延长至超过6周期可能改善总生存。
研究设计与样本
- 法国全国性人群队列研究,纳入2008年新诊断并经组织学确诊的胶质母细胞瘤患者2053例,随访至2015年。
主要发现
- 中位总生存为11.2个月(95%CI 10.7-11.9),男性/女性比例为1.5,中位年龄64岁。
- 13%患者未接受任何肿瘤治疗(仅活检),中位生存1.8个月(95%CI 1.6-2.1)。
- 27%患者接受未包含放疗-替莫唑胺联合的治疗,中位生存5.9个月(95%CI 5.5-6.6)。
- 60%患者接受包含启动放疗-替莫唑胺同期阶段的治疗,中位生存16.4个月(95%CI 15.2-17.4);其中44%患者启动替莫唑胺辅助阶段,中位生存18.9个月(95%CI 18.0-19.8)。
- 仅22%患者接受6周期或以上辅助替莫唑胺,中位生存25.5个月(95%CI 24.0-28.3);多因素分析显示,非进展患者中辅助替莫唑胺用满6周期(标准方案)即停者死亡风险显著高于继续治疗者,HR=1.5(95%CI 1.2-1.9)。
临床怎么用
- 原文结论认为,在非进展患者中,将辅助替莫唑胺延长至超过6周期可能改善总生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma is the most frequent primary malignant brain tumor. In daily practice and at whole country level, oncological care management for glioblastoma patients is not completely known. OBJECTIVES: To describe oncological patterns of care, prognostic factors, and survival for all patients in France with newly-diagnosed and histologically confirmed glioblastoma, and evaluate the impact of extended temozolomide use at the population level. METHODS: Nationwide population-based cohort study including all patients with newly-diagnosed and histologically confirmed glioblastoma in France in 2008 and followed until 2015. RESULTS: Data from 2053 glioblastoma patients were analyzed (male/female ratio 1.5, median age 64 years). Median overall survival (OS) was 11.2 [95% confidence interval (CI) 10.7-11.9] months. The first-line therapy and corresponding median survival (MS, in months) were: 13% did not receive any oncological treatment (biopsy only) (MS = 1.8, 95% CI 1.6-2.1), 27% received treatment without the combination of radiotherapy (RT)-temozolomide (MS = 5.9, 95% CI 5.5-6.6), 60% received treatment including the initiation of the concomitant phase of RT-temozolomide (MS = 16.4, 95% CI 15.2-17.4) whom 44% of patients initiated the temozolomide adjuvant phase (MS = 18.9, 95% CI 18.0-19.8). Only 22% patients received 6 cycles or more of adjuvant temozolomide (MS = 25.5, 95% CI 24.0-28.3). The multivariate analysis showed that the risk of mortality was significantly higher for the non-progressive patients who stopped at 6 cycles (standard protocol) than those who continued the treatment, hazard ratio = 1.5 (95% CI 1.2-1.9). CONCLUSION: In non-progressive patients, prolonging the adjuvant temozolomide beyond 6 cycles may improve OS.
引用
- Fabbro-Peray P, Zouaoui S, Darlix A, et al. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. J Neurooncol. 2018. PMID: 30523606. doi:10.1007/s11060-018-03065-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。